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Sedation in Children: Current Concepts 
Varsha Bhatt-Mehta, Pharm.D., and David A. Rosen, M.D. 
Sedation in children poses a great challenge, with the main concern one of 
safety. The importance of providing adequate sedation to children was 
realized only in the last decade and a half, and relevant data are severely 
lacking. Use of potent sedative agents is not without risk. Children are given 
sedative agents in a wide variety of settings by practitioners with different 
degrees of experience with the drugs and management of adverse effects. 
Controversial issues must be addressed in this area, and appropriate tools 
developed to measure sedation and individualize treatment based on the 
drugs’ pharmacokinetic and pharmacodynamic properties. 
(Pharmacotherapy 1998; 18(4): 790-807) 
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Procedure-Directed Sedation 
Children undergoing m dical car are 
confronted with unfamiliar environments that 
may be perceived as potentially threatening. To 
soothe their fears and anxieties, several 
approaches are available, such as behavioral 
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management, psychology, and pharmacology. A 
multidimensional approach is optimal; however, 
caregivers frequently resort to drug therapy 
because of inadequate time or resources. 
The literature on sedation in children is some- 
what limited, and clinicians make considerable 
extrapolation from adult literature. However, not 
only does the pharmacology of sedative agents 
differ in children compared with adults, but the 
time course of sedation differs. Adults usually 
require most pharmacologic intervention at the 
beginning of an illness, whereas children tend to 
need less at the beginning and more as they 
recover. 
For any medical therapy, it is necessary to have 
an instrument that can detect problems and 
document treatment effectiveness. For sedation, 
developing such a tool is difficult since objective 
data are not  easily obtained. A number of 
scoring systems discriminate different levels of 
sedation, but they have been slow to be accepted. 
The Vancouver Sedative Recovery Scale, which is 
validated for the pediatric intensive care unit 
(PICU) and postanesthesia recovery unit, rates 
12 items in 3 categories-responsiveness, eye 
opening and function, and movements. The 
score is between zero and 22,  with higher 
numbers given to more awake patients.’ 
The Neurobehavioral Assessment Scale (NAS) 
rated behavioral function in adults (age 18-72 
yrs) undergoing maxillofacial procedures and 
was better than the Glasgow Coma Scale in 
differentiating levels of sedation.’ The NAS rates 
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four areas: sedation and reduced alertness, 
disorientation, speech articulation defect, and 
psychomotor retardation. The first three 
provided 97% of variance in scores; the 
contribution of psychomotor retardation may be 
small and its evaluation unnecessary. A more 
objective device that does not require observed 
behavior analyzes the neural network to classify 
electroencephalographic patterns against the 
depth of midazolam sedation during long-term 
sedation in the intensive care unit (ICU).3 Even 
though it successfully classified level of sedation 
in only 50-60% of patients,  the authors  
concluded that the scale compared with visual 
classification alone. However, it is limited in that 
it requires special equipment and expertise, and 
is not easily performed at the bedside. 
We developed a sedation scoring system for 
our PICU (Figure 1). It has not been formally 
validated, but in practice it proved useful. A 
practical problem with validating tools such as 
those intended for the ICU is concomitant 
administration of analgesic agents that act as 
confounders and prevent a true evaluation of the 
efficacy of the sedative agent. Classic, validated 
analgesic scales have little or no application to 
assessment of sedation, although many have tried 
to use them for this purpose. When conscious 
sedation is necessary for procedures such as 
echocardiography and computed tomographic 
(CT) scans,  a simpler tool may be more 
appropriate. A modified version of this scale is 
currently being used at one author’s institution to 
monitor sedation for short procedures. 
Thus, although many scoring systems are 
available to measure depth of sedation, an ideal 
does not exist. Development of such an ideal 
system is hampered by many factors, including 
difficulty eliminating subjectivity from assessment 
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and the complex condition of patients in whom 
such scales might be most useful. 
Pharmacologic Options 
Pharmacologic sedation should not be a 
substitute for analgesics when a child is in pain, 
or for honest explanations about  medical 
maneuvers and attempts at  behavior modification. 
Distraction, relaxation techniques, and positive 
imagery can avoid sedation for many nonpainful 
procedures in which cooperation is necessary. 
These techniques achieved good cooperation in 
children as young as 7 years undergoing right 
heart catheterization for b i~ps i e s .~  Using an age- 
appropriate video tape as an alternative to 
sedative agents, 92% of children (mean age 18.6 
mo) successfully underwent cardiac ultrasound 
without ~edat ion .~  Certainly, when nonpharma- 
cologic modalities fail, sedatives are appropriate. 
General guidelines for sedation such as those 
set forth by the American Academy of Pediatrics 
should be adhered to when the drugs are 
delivered by a nonanesthesiologist.6 These 
guidelines were developed due to increased use 
of sedatives during invasive diagnostic, 
radiologic, and minor  surgical procedures 
performed in children outside the operating 
room. They were issued with the understanding 
that regardless of the intended level of sedation 
or route of administration, sedation represents a 
continuum from a loss of protective reflexes, 
through a light level of sedation, to obtundation. 
The guidelines clearly define the extent of 
physiologic monitoring during various degrees of 
sedation, defined as follows: 
1. Conscious sedation, a medically controlled 
state of depressed consciousness that allows 
the patient’s protective reflexes to be 
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Figure 1. West Virginia University PICU sedation scoring system. 
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maintained, maintains a patent airway 
independently and continuously, and 
permits appropriate responses by the patient 
to physical stimulation or verbal command 
2. Deep sedation, a medically controlled state 
of consciousness or unconsciousness from 
which the patient may not be easily aroused; 
it may be accompanied by partial or complete 
loss of protective reflexes, including inability 
to maintain a patent airway independently 
and respond purposefully to physical 
stimulation or verbal command 
3. General anesthesia, a medically controlled 
state of unconsciousness accompanied by 
loss of protective reflexes, including inability 
to maintain a patent airway independently 
and respond purposefully to physical 
stimulation or verbal command. 
Recommended physiologic monitoring for 
conscious sedation covers baseline vital signs, 
pulse oximetry or equivalent continuously 
during the procedure, intermittent respirations 
and blood pressure, continuous heart rate, and 
airway patency. After the procedure, the child 
should be observed in a well-equipped facility 
(presence of oxygen, bag mask, etc.) with 
frequent vital sign testing. Pulse oximetry and 
continuous heart rate monitoring should 
continue until the patient is fully alert. Deep 
sedation requires more stringent attention, 
including continuous cardiorespiratory monitoring 
with or without mechanical ventilation, and 
frequent blood gas monitoring depending on the 
patient’s condition. This type of sedation is often 
necessary in the ICU. 
For patients undergoing general anesthesia, 
anesthesiologists have minimal monitoring 
standards to which they adhere. Regardless of 
the situation, whenever sedation is required, the 
individual administering and monitoring the 
agent should be different from one performing 
the pr~cedure .~  
Chloral Hydrate 
Experience with chloral hydrate as a sedative is 
extensive. Doses vary from 40-120 mg/kg orally 
or rectally, with the maximum single dose 2 g.’ It 
is generally given to sedate children to allow 
completion of a diagnostic procedure. Thus, in 
most studies, if children achieved a motionless 
state sufficient to allow completion of a 
procedure after receiving a given dose of chloral 
hydrate, the agent was deemed to be a success. 
In a series of 295 patients undergoing CT 
examinations, 7% experienced side effects, with 
vomiting being the most common (4.3%).’ The 
frequencies of hyperactivity and respiratory 
symptoms were less than 2%. 
The success rate for sedation is usually around 
86% for healthy children, whereas in those with 
neurologic disorders it tends to be 10wer.~ In this 
study of 50 children, 43 were successfully 
sedated with a mean chloral hydrate dose of 58 
mg/kg (range 25-81mgkg). Seven patients who 
did not respond to the initial dose had neurologic 
abnormalities including intraventricular 
hemorrhage, cerebral palsy, brain tumors, and 
seizure disorder. Failure to respond ranged from 
being awake during procedures to requiring 
additional doses of chloral hydrate or a different 
agent (unspecified) intramuscularly and 
Because chloral hydrate does not increase 
intraocular pressure, it was recommended in 
children with normal or glaucomatous eyes who 
require ocular pressure measurements. lo The 
suggested dose is 100 mg/kg for the first 10 kg 
body weight, and 50 mgkg for each additional 
kilogram not to exceed 3 g in uncooperative 
children. In our experience this dose is excessive 
for most infants and some children. We 
recommend a starting dose of 50 mg/kg with 
incremental doses of 25 mg/kg up to 100mg/kg, 
not to exceed 1 g in infants and 2 g in older 
children. A different agent may be added if 
response to the maximum dose of chloral hydrate 
is inadequate.” Patients should be monitored 
closely after the procedure because delayed 
respiratory depression can occur with high doses 
of chloral hydrate. Respiratory depression also 
was observed after repeated doses for prolonged 
sedation.12 
Chloral hydrate is perceived as a benign drug 
by many health care professionals, however, it 
can cause adverse effects at normal doses. A 
significant effect on diastolic blood pressure and 
expired carbon dioxide (C02; p<0.02 and <0.005, 
respectively) occurred in 26 healthy children (age 
21-42 mo) who received doses of 25-75 mg/kg.” 
Both values were influenced by the dose and 
were elevated slightly with the highest dose. 
This result must be interpreted with caution, 
since children receiving higher dose were 
sleeping and the entire C02 was routed through 
the nostrils (and therefore diluted by dead space, 
resulting in lower concentration recorded from 
the nostrils); in children who received the lower 
dose and were crying, some COz was expired 
from the mouth. Dental procedures also tend to 
rescheduling procedures. I 
SEDATION IN CHILDREN Bhatt-Mehta and Rosen 793 
have an effect on cardiovascular function (due to 
crying, aggressive struggling, etc.), and this must 
be kept in mind when interpreting the results of 
this study. 
Finally, a carcinogenic potential is associated 
with accumulation of trichloroethylene, a 
metabolite of chloral hydrate. The risk is 
theoretical, and evidence is insufficient to 
warrant selection of an  alternative agent. 
Adverse effects that could result from repeated 
administration of chloral hydrate include central 
nervous system disturbances, decreased albumin 
binding, and metabolic acidosis, and predispose 
newborn infants to hyperbilirubinemia. In 
addition, data are insufficient to establish 
superiority of one sedative over another with 
respect to safety and efficacy. In 1993 the 
American Academy of Pediatrics Committee on 
Drugs issued a statement concluding that the 
drug is an effective sedative with a low frequency 
of toxicity when administered in recommended 
doses in the short term." According to the 
committee, "A sudden switch by physicians and 
dentists from a sedative with which they are 
familiar to one with which they have less 
experience and for which there are not enough 
pharmacologic and safety studies in children may 
pose a greater immediate risk to children than a 
theoretical risk of carcinogenesis from short-term 
sedation with chloral hydrate." Additional well- 
designed studies are necessary to establish safety 
and efficacy of chloral hydrate in children. 
Propofol 
Propofol is one of the newest agents available 
for sedation in children. The ability to go from 
light sedation to general anesthesia and back to 
light sedation in  a short  time makes i t  an  
attractive agent for intravenous sedation. 
Propofol is an oil-soluble drug produced as a soy- 
based emulsion. The constitution and the caloric 
content of the emulsion are equivalent to the 
commercial fat emulsion preparation, Intralipid 
lo%, given as part of total parenteral nutrition. 
A s  such,  the product is prone to bacterial 
~ontamination.'~ The manufacturer's recommen- 
dations are to change the entire propofol 
administration set every 6 hours when ampules 
are used for procedures and every 12 hours when 
glass bottles are used for continuous infusion. l5 
This practice is time consuming and costly. 
Because of limited experience and the potential 
for general anesthesia, the manufacturer 
recommends that propofol be administered under 
the direction of an anesthesiologist. Despite this 
precaution, the drug is being given with 
increasing frequency by, among others, specialists 
in dentistry, radiology, cardiology, and ICU 
personnel. 
For dental procedures (e.g., molar extractions) 
in handicapped patients, propofol has replaced 
nitrous oxide. Initially i t  was given as an 
intravenous infusion of 3 mg/kg/hour and 
gradually increased to 3.6 * 0.65 mg/kg/hour 
during the procedures; this regimen provided 
satisfactory sedation in 90% of patients."j 
Another trial compared sedation with midazolam 
and propofol i n  18 mentally or physically 
handicapped patients age 5-26 years who 
required restorative dental treatment or tooth 
extractions. l7 Induction and recovery times were 
much shorter with propofol than with 
midazolam, and the quality of sedation was 
considered better in  the propofol group. 
Propofol was also preferred by patients and their 
parents since recovery was smoother and faster. 
Before magnetic resonance imaging (MRI)  
studies, 30 children 1-10 years of age received 
induction anesthesia with halothane and nitrous 
oxide followed by a propofol loading dose of 2 
mg/kg.'* General anesthesia was then discontinued 
and propofol started at an infusion rate of 3, 4.5, 
or 6 mg/kg/hour during imaging that lasted for 
55 i 26 minutes. Induction and recovery times 
in  the three groups were not  significantly 
different. No child receiving the highest dosage 
moved during MRI, whereas 30-50% of children 
in the two lower-dosage groups did. No side 
effects such as nausea, vomiting, or significant 
cardiovascular instability occurred in any group. 
The authors recommend 6 mg/kg/hour during 
MRI to achieve maximum sedation and good 
compliance. 
Data on continuous sedation with propofol in 
the PICU are limited.'9-2' The drug's pharmaco- 
kinetics and pharmacodynamics were studied in 
28 PICU patients (age 0.13-182 mo).22 After a 
loading dose of 2.5 mg/kg, infusion rates of 2-15 
mg/kg/hour to achieve and maintain COMFORT 
scores23 in the desired range of 17-26. Plasma 
concentrations at the end of the infusion ranged 
from 0.26-2.6 mg/L, a 10-fold variation. Most 
patients achieved concentrations of less than 1 
mg/L with this regimen. Large interpatient 
variability was observed in pharmacokinetics, 
and no relationship between plasma concentrations 
and effect could be established. The drug .was 
generally well tolerated with the exception of one 
patient who experienced hypotension possibly 
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SCORE = 0 SCORE = 1 SCORE = 2 SCORE = 3 
STOP PROPOFOL DECREASE or A or B 
INFUSION 15 PROFOFOL DECREASE NO CHANGE 
MINUTES 81 INFUSION 5 PROPOFOL 
DECREASE 15 mcglKGlMlN INFUSION 2 
rncgKGlMIN rncgMG/MIN 
due to propofol. 
In our PICU, intravenous boluses of propofol 
0.25 mg/kg are given until an appropriate level of 
sedation is attained. This loading dose is 
followed by a continuous infusion of 3 
mg/kg/hour and titrated upward as necessary. A 
sedation algorithm may be used to adjust  
infusion rates (Figure 2). The algorithm shown 
in Figure 2 is used at our institution and is based 
on a sedation scoring system that was developed 
in-house. In general, the cost of treatment with 
propofol and the development of tolerance to the 
agent limit its use to less than 10 days for 
continuous sedation, although it has been given 
for up to a month without adverse effects to some 
patients.24 
Propofol is associated with many complications, 
including opisthotonus, anaphylaxis (mostly 
bronchospasm and allergic edema), delayed 
recovery, resedation, bradycardia, and seizures.25* 26 
A 22-year-old woman was started on a continuous 
infusion of 50 pg/kg/minute and continued to 
receive the agent for 13 days without hemodynamic, 
pulmonary, or hematologic  complication^.^' The 
dosage of propofol during this time was increased 
to 200 pg/kg/minute, giving the patient a huge 
caloric load and substantially increasing her 
partial pressure of C 0 2 .  The infusion was 
discontinued, and 6 days later the patient had a 
tonic-clonic seizure that required benzodiazepines 
and a high-dose barbiturate to control it. 
I 
SCORE = 4 SCORE = 5 
or C BOLUS 
INCREASE PROPOFOL 
PROPOFOL 0.25 MGKG 
INFUSION 10 INCREASE 
mcg/KGlrnin PROPOFOL 
developed fatal metabolic acidosis and lipemic 
serum.28 The authors speculated that the drug 
may have contributed to the deaths. Two large 
studies of sedation in pediatric patients found no 
association between death and prop~fol.~’ In late 
1992, after reviewing reported cases of propofol- 
associated deaths worldwide, the Food and Drug 
Administration Anesthetic and Life Support Drug 
Advisory Committee conclyded that no direct 
link could be e~tablished.~’ 
Thus, i t  appears that the drug should be 
limited to short-term sedation for procedures. 
Until more experience is gained in the PICU 
setting, it should be administered only if all else 
fails or if the sedation is expected to be of short 
term, generally 24 hours or less. Deep or long- 
term sedation with this agent should be managed 
by an anesthesiologist. 1 
Benzodiazepines 
The availability of newer short-acting 
benzodiazepines and a specific antagonist, 
flumazenil, make this class of agents particularly 
attractive for sedation. Despite widespread 
application, the literature on some of the older 
agents such as lorazepam and diazepam for 
sedation in children is scant, although the drugs 
have been evaluated extensively as premedication 
due to their anxiolytic properties and as 
antiseizure agents. 
Midazolam Five ihildren (age 1 mo-6 yrs) with upper respiratory problems requiring intubation 
received propofol for sedation, after which they Experience with the short-acting benzodiazepine 
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midazolam is rapidly growing in the United 
States. Although i t  is available only in an 
injectable form, it  is administered by several 
routes. Given intravenously, midazolam 0.5 
mg/kg was followed by 0.25 mg/kg at 2-minute 
intervals until sedation was achieved, with a 
maximum dose of 1 mg/kg. Doses as high as 0.6 
mg/kg were completely effective in 47.5% of 57 
children (age 4 mo-10.25 yrs) and partly 
effective (i.e., child struggled but procedure was 
completed successfully) in 38.5% for short 
procedures such as bone marrow aspiration, 
lumbar puncture, thoracentesis, and renal biopsy, 
a s  well as nonpainful procedures such as 
intubation and intravenous p y e l ~ g r a m . ~ ~  The 
investigators reported lack of sedation in 14% of 
children. When effective, onset time was 4.3 
minutes with a mean duration of 88 minutes. No 
hypoventilation occurred. Since the drug has no 
analgesic properties, meperidine up to 1 mg/kg 
was added for painful procedures. As would be 
anticipated, addition of the narcotic decreased 
blood pressure; the mean fall of 6 mm Hg was 
not dose related. 
The results of this study seem somewhat 
paradoxic, since even in normal doses of 0.1 
mg/kg midazolam can cause hypoventilation in 
susceptible patients. The cause for low 
effectiveness at seemingly high doses is not clear 
from the report. It seems prudent to avoid such 
high doses and administer combination therapy, 
rather than continue increasing doses of a single 
agent to unsafe levels i f  lower doses are 
ineffective. 
Although an oral preparation of midazolam is 
not available, the injectable form is often given 
orally. The bitter taste may be masked by 
combining it with flavored liquids or adding it to 
flavored gelatin.32. 33 Doses of 0.1-1 mg/kg have 
been given orally, but 0.5 mg/kg appears to be 
most effective, with minimal adverse effects. The 
onset of effect after oral administration is about 
10-30 minutes, and the failure rate is 20%.34 
Thirty children (age 1-6 yrs) scheduled for 
outpatient surgery were separated from their 
parents 10, 20, or 30 minutes after oral 
administration of midazolam 0.5 mg/kg.35 
Sedation and anxiolysis were assessed by two 
blinded observers at baseline, at the time of 
separation from parents, and at the time of 
induction of anesthesia. No difference in extent 
of anxiolysis was seen 10, 20, or 30 minutes after 
drug administration. 
The intranasal route of midazolam 
administration is popular, although the failure 
rate is about 20%.36 This route is often chosen 
because of its rapid onset and lack of need for 
patient cooperation. A limitation is that when 
large drug volumes are needed, the drug is not 
absorbed by the nasal mucosa but is delivered to 
the posterior pharynx where i t  is swallowed. 
Burning in the nose and eyes and occasional 
epistaxis make this route less popular for repeat 
administration. The recommended intranasal 
dose is 0.2-0.4 mg/kg. 
Midazolam 0.3 mg/kg administered rectally is 
also effective, with onset of sedative effect 
generally within 20-30 minutes after 
admini~tration.~',  38 To administer midazolam 
rectally, the parenteral preparation was 
appropriately diluted and drawn up into a 10-ml 
syringe.38 The syringe was connected to a gel- 
lubricated 3.5-mm outside diameter pediatric 
feeding tube, and the tube inserted about 3-4 cm 
into the rectum. After administration, the tube 
was flushed with 2 ml of air. 
In the ICU, midazolam is administered by 
continuous infusion much as originally 
described.39 Infusion rates of 0.4-4 pg/kg/minute 
after a bolus of 0.25 mg/kg appear to be a safe 
and effective (Figure 3).39- 40 Combining 
midazolam with other drugs with sedative 
properties enhances the effectiveness of 
midazolam. After cardiothoracic surgery, 24 
critically ill children were adequately sedated 
with midazolam 0.8-6.6 pg/kg/minute plus 
fentanyl 0.008-0.4 pg/kg/minute for analgesia.41 
This combination for sedation is not without 
complications. Respiratory arrest was reported 
after relatively normal dosages of the two agents 
administered together.42 
Emergence delirium occurred in a 26-month- 
old child who received midazolam 0.5 mg/kg 
orally in  grape juice before repair of a 
l a~e ra t ion .~~  Approximately 20 minutes after the 
dose, the laceration was sutured, and the child 
was observed for a further 40 minutes and 
discharged without complications. Approximately 
1.5 hours after receiving midazolam (30 min 
after discharge), the child became extremely 
agitated and was brought to the emergency 
department. The signs of delirium included 
shrieking, hypervigilance, and fright. After 45 
minutes of supportive care and observation, the 
child returned to her normal status and was 
discharged. 
Midazolam is a short-acting agent and it is 
popular for conscious sedation. However,. one 
should be aware of such paradoxic responses, 
and observation should probably continue for at 
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least 1-2 hours after a dose since peak concen- 
trations in plasma after an oral dose occur at 
about that time. 
Lo razepam 
Lorazepam is useful for long-term sedation in 
the ICU. Due to its long half-life in neonates and 
infants i t  can be administered as a bolus dose 
every 6-8 According to practice 
guidelines for intravenous sedation and analgesia 
published by the Society of Critical Care 
Medicine, lorazepam is preferred for prolonged 
treatment of anxiety in critically ill patients.45 
Despite its abundant use in children, minimal 
data are available on its pharmacodynamics and 
pharmacokinetics during long-term sedation. 
After a single low dose of lorazepam 0.03 
mg/kg in 16 children (age 2.8-16 yrs), the trend 
was toward decreased anxiety by 24 hours, with 
some antegrade amnestic The terminal 
half-life of lorazepam was reported at 10.5 * 2.9 
hours. Continuous infusions for long-term 
sedation in the ICU was reported.46 However, 
there is very little information on appropriate 
dosage, correct infusion concentrations, and 
compatibility with other intravenously admin- 
MI DAZOLAM 
(0.25 MGIKG) 
-7- 
0.4-4 rncg/KG/MlN 
BEGIN AT 1 rncg/KG/MIN 
TITRATE TO ACHIEVE 
INFUSION 
FOR 30 
MINUTES 
AND RESTART 
KETAMINE 15 
rncg/KG/MIN 
DECREASE 
KETAMINE 
INFUSION BY 
1 rncg/KG/MIN 
istered drugs. The last is important for children, 
in whom intravenous access is often at  a 
premium, making coinfusion of drugs necessary. 
A randomized comparison of lorazepm and 
midazolam in adults reported that lorazepam was 
superior for time to return to baseline mental 
status.46 This could potentially shorten the ICU 
stay and reduce costs. The authors  also 
suggested that dosages of benzodiazepines 
required for sedation may be higher than 
currently recommended in the l i terature.  
Another author also found that continuous 
infusions of lorazepam were cheaper and more 
cost effective than midazolam by that route47; 
however, that report was based on data collected 
during the course of the author’s day-to-day 
practice and did not stem from a controlled 
study, so the results should be interpreted ,with 
caution. 
Finally, very ,large volumes of fluid may be 
required to deliver continuous sedation since 
lorazepam’s compatibility with various intravenous 
fluids in concentrations greater than 0.16 mg/ml 
and its adherence to the polyvinyl and polyolefin 
bags are major  problem^.^'. 49 In children in 
whom intravenous access is difficult, continuous 
infusions may not be feasible due to lack of data 
IF UNABLE TO ACHIEVE A SCORE 
OF 3 WITH MIDAZOIAM ALONE. 
TO A SCORE OF 3 
LOAD KETAMINE 0.1-0.5 MGlKG 
INFUSE KETAMINE 
10-70 rncg/KG/MIN 
BEGIN KETAMINE AT 
45 rncg/KG/MIN 
SCORE = 3 
or B 
UNCHANGED 
KETAMINE INCREASE 
INFUSION BY KETAMINE 
10 rncglKGIMIN INFUSION BY 
18 mcg/KG/MlN 
Figure 3. Algorithm for adjusting midazolam and ketamine infusion rates, based on the West Virginia University PlCU 
sedation scoring system. 
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on compatibility of lorazepam with common 
intravenous fluids such as parenteral nutrient 
solutions. 
Rhythmic, myoclonic jerks occurred as early as 
1 minute after administration of lorazepam to 
premature infants.50 The author hypothesized 
that alcoholic solvents in the injection formulation 
may be responsible for this neurotoxicity and 
recommended avoiding them whenever possible. 
Benzodiazepine solutions for oral administration 
prepared in propylene glycol and polyethylene 
glycol tend to cause diarrhea and should be 
a~oided .~ '  
Diazepam 
Diazepam, although considered a prototype 
intravenous sedative agent, has not  been a 
popular sedative agent since the introduction of 
the shorter acting agents such as midazolam. 
The Society of Critical Care Medicine no longer 
recommends it for critically ill ICU patients due 
to pain and thrombophlebitis that usually occur 
when administered peripherally; its long duration 
of action, which may potentially cause 
oversedation due to accumulation; and large fluid 
volumes that may be required in continuous 
infusion.45 Its main indications remain the 
treatment of status epilepticus and for short 
procedures such as endoscopy and radiation 
therapy (see below). 
Ketamine 
Ketamine provides sedation with minimal 
respiratory and hemodynamic compromise, and 
has the advantage of inherent analgesic proper- 
ties due to effects on the opioid and serotonergic 
systems. Its bronchodilatory properties make it 
an attractive drug when sedating patients with 
asthma. However, ketamine produces copious 
airway secretions and may also increase airway 
responsiveness with possible la ryngospa~m.~~~ 53 
An oral preparation is not available, but similar 
to midazolam, the drug may be administered 
orally by mixing the injection formulation with a 
beverage. However, failure rates as high as 35% 
have been reported with this route. Oral sedation 
is usually begun with 5 mg/kg for patients with 
normal mentation, although doses have ranged 
from 1-10 mg/kg.34* 54 Time to onset is about 20 
minutes, similar to that of midazolam, but 
recovery time is slightly longer. The frequency of 
nausea and vomiting also is higher for ketamine 
than for midazolam. 
In mentally handicapped patients, the required 
oral dose is increased and appears to correlate 
with level of impairment. In severely handicapped 
patients, a higher starting dose of 8 mg/kg attains 
adequate sedation, and doses as high as 36 mg/kg 
may be required in profoundly mentally 
handicapped  patient^.^^-^' 
Like midazolam, ketamine is effective 
intranasally. A dose of 6 mg/kg is recommended. 
Time to onset is 20-40 minutes, with a success 
rate of 78%.58 Rectally administered ketamine 5 
mg/kg is also efficacious; time to onset is similar 
to that with other routes of admini~tration.~~ 
In a case series reported in 1989, ketamine 4 
mg/kg intramuscularly was administered to 
children in an emergency department to facilitate 
various  procedure^.^' In most children, adequate 
conditions for performing the procedures were 
reached within 5 minutes, and 86% of procedures 
were completed without  additional local 
anesthetic agents. The only clinically significant 
complication was a single case of laryngospasm 
that did not require intubation. 
Ketamine is often given for sedation in the 
cardiac catheterization laboratory. By keeping 
the incremental dose low (0.5-1 mg/kg 
intravenously), the frequency of respiratory 
compromise such as central apnea was reduced 
to 3% in 157 patients age 1 month-20 years.60 
The drug is particularly effective in this setting 
because it does not suppress aberrant cardiac 
conduction pathways, as do other sedative and 
analgesic agents such as morphine. 
Alterations in hemodynamics associated with 
ketamine for sedation are said to be small.61 This 
finding was challenged, however, as the drug was 
implicated in the production of pulmonary 
hypertension in a limited number of patients 
with baseline elevated pulmonary vascular 
resistance.6z In these patients ketamine 
consistently increased oxygen consumption and 
raised pulmonary artery pressure. 
In the PICU ketamine is administered by 
continuous intravenous infusion, especially in 
patients who have undergone cardiac surgery. 
Children undergoing cardiac surgery, and those 
requiring intubation for exacerbation of under- 
lying pulmonary disease such as bronchopulmonary 
dysplasia, were given a continuous intravenous 
infusion of 10-15 and 16-32 pg/kg/minute, 
r e s p e c t i ~ e l y . ~ ~ ,  64 A t  these dosages, some 
supplemental midazolam was required. One 
group also administered a 1-mg/kg starting dose.63 
In the PICU at our institution, when ketamine 
infusion is given for continuous sedation the 
patient receives a loading dose of up  to 0.5 
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mg/kg, followed by a continuous infusion of 
1 0-70 pg/kg/minu t e , with up ward t i t  ra t io n 
depending on the sedation score (Figure 3 ) .  
When given for long-term sedation (generally 
> 48-72 hrs), the infusion rate should be kept as 
low as possible to minimize the occurrence of 
myoclonic movements when the drug  is 
removed. We observed myoclonic movements 
persisting for a month after cessation of therapy. 
The psychomimetic side effects of ketamine, 
such  as vivid dreams and confusion on  
emergence from sedat ion,  are reduced by 
benzodiazepines such as midazolam. Hence the 
combination is desirable to minimize these 
psychic adverse effects, which are most obvious 
in adults but could occur in children as well.64 
Thus, although ketamine is an alternative for 
sedation in the PICU, it  should be prescribed 
with extreme care, preferably under the guidance 
of an anesthesiologist, since it has a potential for 
serious adverse effects. 
Barbiturates 
Barbiturates have considerable sedative 
properties. Compared with many newer drugs, 
they have longer duration of action and narrower 
therapeutic indexes. Familiarity with 
barbiturates,  several available routes of 
administration, and the ability to combine them 
with drugs from other classes make them a 
frequent choice. Pentobarbital, secobarbital, and 
methohexital are given for short-term conscious 
sedation for special procedures such as CT scans 
and radiation t h e r a ~ y . ~ ~ - ~ '  
Pentobarbital 2.5-7.5 mg/kg intravenously 
successfully provided sedation in children before 
MRI scans.66 Secobarbital provides effective 
sedation for newborns in the ICU. Because of its 
long durat ion of action and possibility of 
accumulation, prolonged sedation can occur, but 
it can be avoided by keeping the dosage below 7 
m g / k g / d a ~ ~ ~  
Methohexital has a rapid onset and a fairly 
short duration of effect. An advantage in the 
pediatric setting is its effectiveness by several 
routes of administration, including intravenous, 
intramuscular, and rectal. The ability to give it 
intramuscularly makes i t  preferred over 
thiopental. In doses of 10 mg/kg intramuscularly, 
sedation for CT scans lasts for 35 minutes, with a 
failure rate of 33%. One group supplemented 
patients with ketamine 1-2 mg/kg if sedation 
with methohexital was inadequate.68 Rectal 
methohexital 25 mg/kg was given before MRI 
with a success rate of 87%.69 In this study, 190 
children requiring sedation for MRI or CT scans 
were sedated with rectal methohexital (102 
patients, mean age 25 * 2 mo) or oral chloral 
hydrate (88, mean age 28 i 3 mo). The drugs 
provided adequate sedation in 87% and 83% of 
patients, respectively. In many cases the duration 
of sedation with methohexital was shorter than 
the M R I ,  result ing in imdequa te  studies. 
Children sedated with chloral hydrate required a 
longer period of observation in the radiology 
department. 
Intravenous methohexital  is effective in 
children with cancer for painful procedures such 
as bone marrow biopsies and radiation therapy. 
In one study, incremental doses were 1 mg/kg, 
the mean total dose required for sedation was 5.6 
mg/kg, and the duration of sedation wad 30 
 minute^.^' Clinically insignificant decreases in 
diastolic blood pressure and  ventilation 
complications requiring bag mask and simple 
suctioning occurred in  1'7.4% and 1.5% of 
patients, respectively. Other minor complications 
requiring no intervention, such as transient 
behavioral changes, transient myoclonus, and 
minimal stridor, occurred in six patients. 
Although barbiturates are effective and 
relatively safe sedative agents, it is essential to 
monitor hemodynamics and oxygenation, and 
have available emergency respiratory support 
equipment for intubat ion when they are 
admini~tered .~ '  The agents do not have any 
analgesic properties, so for painful procedures, 
analgesics should be added to the sedative 
regimen. 
Narcotics 
Narcotics are widely used for sedation; 
however, administration for prolonged periods in 
the absence of pain leads to physical dependence. 
Morphine is the prototype, but  synthetic 
narcotics such as fentanyl and alfentanil are 
increasingly popular and are less sedating than 
the natural opioid compounds. 
Alfentanil 
Alfentanil is the shortest-acting of approved 
narcotics. It is effective for continuous sedation 
during cardiac catheterization in children after 
premedication with a benzodiazepine such as 
midazolam. During cardiac catheterization, 14 
infants (age 1-17 mo) were sedated with 
alfentanil 24 * 8 pg/kg initial bolus dose followed 
by 32 * 8 pg/kg/hour infusion.71 In cyanotic 
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versus acyanotic infants, mean * SD dosages were 
21 * 6 versus 28 i 8 pg/kg/hour. Cyanotic 
infants received the lower dosage as a precaution 
against further worsening of respiratory status, 
since all narcotics have a potential to suppress 
respiration. 
Alfentanil with fentanyl were compared during 
cardiac catheterization in 13 patients age 1-23 
months.72 Initial bolus doses were 20 * 6 and 2.5 
* 1.1 pg/kg, respectively, they were followed by 
intravenous infusions of 30 i 12 and 1.5 * 0.6 
pg/kg/hour, respectively. Drug requirements were 
comparable for all patients regardless of age or 
oxygen saturation in blood. The frequency of 
nausea and vomiting after sedation as well as 
length of sedation were comparable for both 
agents. 
Another study of patients undergoing a Fontan 
procedure compared alfentanil with f e n t a n ~ l . ~ ~  
The loading dose was decreased to 4.4 * 2.7 
pg/kg and the intravenous infusion to 10.3 i 8.6 
pg/kg/hour. These doses were lower than those 
for surgical anesthesia and are explained by a 
lower degree of noxious stimulation associated 
with cardiac catheterization than with cardiac 
surgery. The regimen produced successful 
sedation in all 14 patients (age 5-20 yrs). 
The potential  for respiratory depression 
requires that patients receiving alfentanil be 
observed closely in the immediate postoperative 
period. For this reason, administration of the drug 
outside the operating room is not recommended. 
Fentanyl 
Fentanyl is given to provide sedation in ICUs 
as well as for special procedures. In one study, 
patients undergoing cardiac catheterization 
received an initial intravenous bolus dose of 
fentanyl 2.5 pg/kg followed by a continuous 
infusion at 1 SO pg/kg/hour. Concerns regarding 
airway safety may require the presence of an 
anesthesiologist for this type of sedation.72 
Fentanyl 0.68 i 0.24 pg/kg/hour was given by 
continuous infusion for 86 * 47 hours  to 
neonates and preterm infants in the neonatal ICU 
to determine its sedative and analgesic  effect^.'^ 
Although it was effective and required fewer 
supplemental  sedative doses as well as 
catecholamines, meconium was excreted later 
and higher bilirubin levels were reached earlier 
than in patients not receiving the agent. Heart 
rate and blood pressure were not significantly 
changed by fentanyl. The drug should be 
administered to neonates under strict indication, 
and the duration of therapy should be limited to 
as short a time as possible to avoid undesirable 
adverse effects, including tolerance. 
For pediatric patients who do not have 
indwelling catheters, the preferred route of 
fentanyl administration is transmucosal. Oral 
transmucosal fentanyl citrate (OTFC) is available 
in a lollipop form and has bioavailability of 
approximately 50%. In 10 patients (age 6-34 
yrs) in a study conducted in an emergency 
department, OTFC was administered in two 
doses, 10-15 pg/kg and 15-20 pg/kg, based on 
extent of patient discomfort, type of procedure 
(laceration repair, abscess drainage, etc.), and 
degree of pain associated with it.75 Patients were 
asked to suck an appropriate lollipop as fast as 
they could. The average dose consumed was 
13.7 * 2.4 pg/kg. Patients required approximately 
12 minutes to consume the dose. Sixty percent 
of patients became sedated in 12-30 minutes 
after starting OTFC consumption. N o  hemo- 
dynamic adverse effects were noted. 
Plasma fentanyl concentrations peak in about 
20-30 minutes,  and in healthy volunteers 
bioavailability is 50%.76 The most common side 
effects of OTFC are pruritus, dizziness, and dry 
mouth; nausea and vomiting have also been 
reported.75 
Sufentani 1 
No studies have compared synthetic narcotics, 
but a major impact of this form of sedation is 
cost. Sufentanil is more expensive than alfentanil 
or  fentanyl and is much more potent than 
fentanyl. Its use outside the operating room is 
extremely limited, although it may be given in 
the PICU. Like fentanyl and alfentanil, when 
sufentanil is administered outside the operating 
room, it should be under the strict supervision of 
an anesthesiologist. Due its high potency, it is 
useful in patients with fluid restriction who 
require high dosages of narcotics, since the drug’s 
fluid volume is considerably less than that of 
fentanyl. 
Su fen tanil 0 .O 13-0.0 1 7 pg/kg/minu te was 
given by intravenous infusion and titrated down 
to 0.004-0.006 pg/kg/minute when it was time to 
wean patients from the ~en t i l a to r .~~  Whereas no 
obvious complications occurred at any time 
during this study, including in the weaning 
period, the authors cautioned against admivis- 
tering the drug to hypovolemic patients in whom 
hypotension could occur at those dosages. 
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Volatile and Inhalational Agents 
Isoflurane may be given for continuous 
sedation in the PICU, but hallucinations, 
generalized seizures, and disorientation may 
occur after its withdrawal and may last for up to 
5 days.7' Isoflurane was administered for 
sedation in the PICU at concentrations ranging 
from 0.1-0.6% in an air-oxygen mixture and 
compared with midazolam 0.02-0.2 mg/kg/hour 
in patients requiring sedation for more than 24 
Sedation was rated on a 6-point scale. 
The agents were discontinued when patients 
were ready to come off the ventilator. Plasma 
isoflurane, midazolam, and 1-hydroxy 
midazolam concentrations did not correlate with 
sedation scores. No undesirable side effects were 
associated with either agent. The authors 
concluded that isoflurane is a suitable alternative 
for sedation of mechanically ventilated patients 
who require long-term (> 24 hrs) sedation. 
A crossover study compared propofol and 
isoflurane in 24 medical and surgical patients 
requiring sedation.a0 No clinically significant 
differences between agents were seen in  the 
quality of sedation or time to recovery from 
sedation. Two patients developed peripheral 
neuropathy. They were randomized to receive 
propofol for 24 hours followed by isoflurane for 
as long as sedation was necessary. They received 
isoflurane for 151 and 254 hours, respectively, 
compared with other patients in whom duration 
of therapy was 10-147 hours. The peripheral 
neuropathy resolved over 4-12 months in these 
patients. It does appear to be a problem with 
prolonged isoflurane administration. 
Other problems associated with volatile agents 
are decreased sedation during airway treatments 
and trachea suctioning, and severe auditory and 
visual hallucinations, as occurred in  three 
patients in this study." Thus, i t  seems that 
isoflurane is a potent agent with many adverse 
effects associated with short- and long-term 
administration. I t  is recommended that it be 
given under the direct supervision of an 
anesthesiologist. 
Nitrous oxide is different from other common 
volatile agents (halothane, isoflurane) in that it 
has analgesic properties. Nitrous oxide at a 
concentration of 35% was widely administered in 
dental studies to augment sedation and analgesia. 
Adding i t  to hydroxyzine preoperatively 
produced better sedation than either alone.81 The 
major problem with volatile agents for sedation is 
adequate scavenging of waste gases. 
Other Agents 
az-Adrenergic Agonists 
The a*-adrenergic agonists such as clonidine 
have emerged as a group of sedative agents that 
cause no or minimal respiratory depression a t  
therapeutic dosages. They also have analgesic 
properties because they prevent the release of 
substance P, a mediator of nosiceptive stimuli. 
The dose of clonidine for sedation is 3-5 
pg/kg. In normotensive children, this does not 
produce hypotension, although bradycardia was 
reported.'* When drugs in this class are given in 
combination with other sedative agents, caution 
must be exercised because of potential for 
excessive sedation. This may be explained by 
alteration in distribution of the second drug 
The literature on these agents is limited. As 
new information accumulates the drugs may 
emerge as effective for sedation. 
being induced by the az-agoni~t.'~ I 
Procedure-Directed Sedation 
CT Scans and MRI 
Sedation is required to keep patients 
motionless during imaging procedures that last 
for more than a few minutes. Patients 
undergoing MRI require deep sedation, since, 
compared with CT scans, the tunnel they are 
placed in is longer and more confining, and the 
procedure is noisy. The MRIs usually last for 
30-60 minutes, and a typical CT scan lasts for 
15-30 minutes. 
According to a national survey of sedation 
practices during CT scans, chloral hydrate was 
the most commonly administered druga4 In a 
retrospective analysis of sedation for CT and MRI 
procedures in 1158 children age 1 day-18 years, 
in children younger than 18 months oral chloral 
hydrate 60-120 mgkg was the most common 
agent.a5 For those older than 18 months, the 
drug of choice was intravenous pentobarbital 2-6 
mg/kg. For 407 outpatients who underwent CT, 
the combined success rate for both regimens was 
97%. Of 765 patients who underwent MRI, 725 
achieved successful sedation, with a success rate 
of 96% for the regimens combined. In another 
study, rectal midazolam 0.3-0.6 mgkg produced 
satisfactory sedation in only 58% of patients.a6 
In one comparison trial, methohexital 25 
mg/kg was administered rectally after diluting the 
injection preparation to 10% solution with sterile 
water.69 Doses were repeated every 15 minutes to 
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a maximum of 500 mg if the child was not 
sedated adequately with the initial dose. Chloral 
hydrate was administered orally as a single dose 
of 50-100 mg/kg and repeated as necessary to a 
maximum of 1000 mg. Sleep time was shorter 
with methohexital (46 vs 66 min), resulting in 
fewer successfully completed MRI scans (69%) 
compared with chloral hydrate (85%). The 
shorter half-life (2-4 hrs) of methohexital 
compared with chloral hydrate (10-12 hrs) 
meant that children could be discharged sooner. 
For CT scans, methohexital was superior to 
chloral hydrate (97% vs 77%). 
Propofol is often chosen for MRI in patients 
who are difficult to sedate because of precise 
control over sedation that i t  provides. A 
comparative study evaluated pentobarbital given 
in incremental doses of 2.5 mg/kg until  
satisfactory sedation was achieved, with a 
maximum dose of 7.5 mg/kg, and propofol 2 
mg/kg followed by supplemental doses of 1 
mg/kg until sedation was satisfactory. The level 
of sedation was maintained with a continuous 
intravenous infusion of propofol 6 mg/kg/hour. 
Both drugs were effective, but the group receiving 
propofol had a higher frequency of oxygen 
desaturation and bradycardia than the pento- 
barbital group.45 This reemphasizes the need for 
the presence of an anesthesiologist during 
propofol sedation. 
Echocardiogram 
Echocardiogram is a noninvasive procedure, 
but positioning the electrical probe on the chest 
and the pressure applied during imaging can 
cause discomfort and patient movement, which 
could affect the results. Thus, these patients are 
sedated. The room where echocardiograms are 
performed is usually dark, which augments 
sedation. 
The efficacy of oral or rectal chloral hydrate 
and thiamylal was evaluated prospectively in 45 
infants, children, and teenagers (age 1 day-19 
yrs) who underwent cardiac catheterization and 
two-dimensional Doppler echocardiographic 
examinat i~n.~ '  Oral or rectal chloral hydrate 
50-70 mg/kg or  thiamylal 22 mg/kg was 
necessary to provide sufficient sedation, and were 
equally efficacious. A problem with chloral 
hydrate is the lag time associated with onset of 
sedation. 
Intranasal midazolam 0.2 mg/kg was given to 
15 infants (age 4-36 mo) undergoing echo- 
cardiograph, with the dose repeated in 5-15 
minutes as necessary.88 All but one examination 
was completed successfully. In the one that 
failed, the second dose was lower than 0.2 mg/kg 
and given at 15 minutes, which was late for that 
patient. The authors recommended 0.2 mg/kg 
for both starting and repeat doses, and if a repeat 
dose is necessary (uncooperative or agitated 
child), i t  should be administered as early as 5 
minutes after the initial one. 
Intranasal midazolam is absorbed much faster 
and therefore its relative safety compared with 
oral midazolam may be much lower. Adverse 
effects such as apnea could occur easily with this 
route of administration. Although the literature 
contains reports of its administration by 
nonanesthesiologists, extreme caution should be 
exercised when it is given by individuals with 
little or no experience with the intranasal route. 
Dental Procedures 
Children may require sedation during dental 
procedures not only to reduce discomfort due to 
being confined in the chair, but because of pain 
and apprehension. Midazolam given rectally was 
more effective than when given orally to 
uncooperative children.89 Studies found that, 
compared with oral administration, with rectal 
administration the procedure could be started 
sooner, the duration of sedation after procedure 
was shorter, and a lower dose was g i ~ e n . ~ ' , ~ ~  
In a study of 24 children (age 18-48 mo) the 
combination of chloral hydrate 50 mg/kg and 
promethazine 1 mg/kg orally was no more 
effective than meperidine 1 mg/kg and 
promethazine 1 mg/kg orally in  providing 
sedation for dental procedures; 48-50% of 
patients in both regimens had a significant 
frequency of oxygen desat~rat ion.~~.  '' Other side 
effects were nausea and vomiting. Chloral 
hydrate-promethazine had significantly better 
results for sleep (p=O.OOl) and overall behavior 
In a double-blind, crossover study of 20 
children (age 20-60 mo) chloral hydrate 50 
mg/kg plus hydroxyzine 25 mg/kg or temazepam 
0.3 mgkg (route of administration unspecified) 
produced similar sedation and no significant 
difference in frequency of desaturation or overall 
beha~ior. '~ In another dental study comparing 
chloral hydrate-promethazine with hydroxyzine- 
diazepam, the latter combination led to 
significantly better behavior (p<0.05) than the 
former.94 Oral triazolam 0.02 mg/kg and chloral 
hydrate 40 mg/kg plus hydroxyzine 25 mg/kg 
(p=O.O19). 
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provided similar sedation.95 
The chloral hydrate dose was increased to 50 
mg/kg, the hydroxyzine pamoate dose remained 
25 mg/kg, and meperidine 1.5 mg/kg was added 
to the regimen.96 All drugs were administered 
orally. This combination led to better behavior 
than the protocol without meperidine and was 
associated with no increases in side effects. 
However, a similar study that gave chloral 
hydrate 40 mg/kg and meperidine 0.5 mg/kg, and 
maintained the hydroxyzine dose at 25 mg/kg 
showed no benefit to the addition of 
m e ~ e r i d i n e . ~ ~  The results of these studies 
suggest that the combination of chloral hydrate 
50 mg/kg, hydroxyzine 25 mg/kg, and 
meperidine 1.5 mg/kg would achieve optimal 
dental sedation. 
Ketamine 6 mgkg (injection preparation given 
orally) was compared with oral meperidine 2 
mg/kg plus promethazine 0.5 mg/kg in  40 
children (age 20-60 mo) undergoing a variety of 
outpatient dental procedures. Ketamine provided 
more rapid sedation than the combination 
regimen. The overall quality of sedation and 
time to recovery were marginally different 
between the groups; however, ketamine was 
associated with more ~ o m i t i n g . ~ '  When 
submucosal morphine 0.15 mgkg was compared 
with oral meperidine 2.2 mg/kg, both 
administered with promethazine 1.1 mgkg orally, 
to children (age 2-7 yrs) undergoing dental 
procedures, no differences were seen in overall 
effectiveness or sedation.99 
Intensive sedation for extremely painful dental 
procedures may require general anesthesia. 
Midazolam and propofol were compared for such 
procedures in a double-blind, crossover study in 
handicapped patients.17 A bolus dose of 
midazolam 0.02 mg/kg was followed by a 
cont inuous infusion of 6.6 pg/kg/minute. 
Propofol 0.2 mg/kg bolus was followed by 4 
mg/kg/hour. Midazolam was inferior to propofol, 
since induction time was less predictable and 
recovery took longer. 
In summary, morphine can be substituted for 
meperidine,  and triazolam, diazepam, or 
midazolam for chloral  hydrate to provide 
sedation for pediatric outpatient dental  
procedures. In mentally or physically retarded or 
combative patients who are very difficult to 
handle, oral ketamine in place of chloral hydrate 
appears to be advantageous. Pulse oximetry 
should be performed for any sedated patient 
requiring these agents. Adverse effects such as 
nausea and vomiting may be expected. Potent 
drugs such as ketamine, propofol, and midazolam 
should be handled only by experienced personnel. 
Oncology Procedures 
A number of comparative studies investigated 
sedative regimens that might be effective in this 
group of patients. In a comparison of midazolam 
and fentanyl for premedication before painful 
procedures in 25 patients, midazolam was 
preferred by most patients due to the amnesia it 
produced. loo 
Midazolam and propofol were assessed in 90 
children and adults who required central venous 
access for chemotherapy or total parenteral 
nutrition.lol Results were similar for midazolam 
0.02 mg/kg initial intravenous bolus repeated 
every 2 minutes until a predefined leve of 
sedation was achieved. This level of sedation was 
then maintained, using 0.005-mgkg increments. 
Propofol 0.75-1 .O mg/kg initial intravenous 
bolus was followed by 0.25-mgIkg bolus, or 
infusion of 2-4 mg/kg/hour to achieve the same 
predefined level of sedation during central line 
placement. Both drugs provided excellent 
sedation with minimal side effects. Midazolam 
produced the best amnesia and propofol (bolus 
and infusion) the fastest recovery. The time to 
reach the predefined level of sedation was 
significantly shorter with the propofol bolus than 
with midazolam and propofol infusion 
(peO.0001). Propofol infusion led to faster 
recovery than the bolus despite the fact that 
higher dosages were necessary to achieve the 
sedation level in this group. The authors concluded 
that the optimal approach is midazolam bolus 
followed by propofol infusion. 
IJ 
Intensive Care Procedures 
Seven sedative regimens for ICU analgesia and 
sedation were compared. lo2 For ventilated 
patients fentanyl-midazolam and alfentanil- 
midazolam combinations were superior to 
ketamine, flunitrazepam, meperidine, promethazine, 
and meperidine-flunitrazepam. Sedation was 
similar with propofol and isoflurane." Propofol 
was infused at a rate of 6-150 pg/kg/minute and 
the inhaled isoflurane concentrations ranged 
from 0.1-0.8%. 
Sedation is often chosen in ICUs to achieve the 
optimum oxygen supp1y:demand ratio. In a 
comparison of sedation with propofol, 
midazolam, thiopentone, and fentanyl, propofol 
reduced oxygen uptake (VOZ) the most (15%), 
followed by midazolam (12%) and thiopentone 
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Table 1. Pediatric Withdrawal Scoring System 
Signs and Symptoms Score Signs and Symptoms Score 
Crying Sweating 1 
Excessive 2 Fever 1 
Continuous 3 100-101°F 1 
Sleep after feeding > 101°F 2 
< 1 hr 3 White blood cells > 20,000 3 
< 2 hrs 2 Mottling 1 
< 3 hrs 1 Nasal stuffiness 1 
Hyperactive 2 10% above normal 1 
Markedly hyperactive 3 10% above normal + retractions 2 
Tremors Sneezing 1 
Mildly disturbed 1 Nasal flaring 2 
Moderate-severely disturbed 2 Excessive sucking 1 
Mildly undisturbed 3 Poor feeding 2 
Moderate-severely undisturbed 4 Regurgitation 2 
Increased muscle tone 2 Projectile vomiting 3 
Yawning 1 Stools 
Excoriation 1 Loose 2 
Seizures 5 Watery 3 
White blood cells > 20,000, no fever 4 Peripheral erythema 3 
Moro reflex Respiratory rate 
Scores above 8 are considered withdrawal. 
From reference 107. 
(10%).lo3 Of interest, fentanyl raised V 0 2  by 5%. 
Endoscopy 
Various doses of meperidine and diazepam in 
combination for endoscopy were compared in a 
randomized double-blind trial. Meperidine 2 
mgkg was superior to meperidine 1 mg/kg plus 
diazepam 0.1 mg/kg, meperidine 2 mg/kg plus 
diazepam 0.1 mg/kg, and diazepam 0.1 mg/kg 
a10ne.l '~ Addition of the benzodiazepine 
increased the frequency of negative behaviors 
such as need for emotional support, verbal 
resistance, verbal fear, unintelligible verbalization, 
crying, and screaming in 9% of the 71 patients 
age 1-19 years. 
Withdrawal of Sedative Agents 
Although sedation is often necessary for 
successful interventions, ceasing sedation is often 
associated with difficulties. Withdrawal reactions 
are fairly common. Unfortunately, the literature 
on methods of weaning sedation is extremely 
limited. 
All 23 children (age 1 wk-22 mo) who were 
sedated with fentanyl for a total dose of 2.5 
mg/kg or for more than 9 days experienced 
withdrawal reaction.lo5 The reaction may also 
occur in children who receive propofol infusion 
for 4 or more days in whom the drug is stopped 
abruptly. Withdrawal has been reported in two 
children age 15 months and 2 weeks, 
respectively, who received midazolam for 2-4 
weeks. lo6 Abrupt discontinuation of midazolam 
led to restlessness, tachycardia, hyperpyrexia, 
and aerophagia in one child. In both patients, 
midazolam was reinstituted and later substituted 
with clorazepate from which they were weaned 
successfully. 
In children, withdrawal from sedation is often 
associated with aerophagia and distention of the 
stomach, leading to vomiting. In addition, it may 
precipitate fever and cardiac, respiratory, and 
neurologic effects. Careful weaning from long- 
term sedation is therefore important.lo6 
Withdrawal symptoms must be evaluated 
critically so that they may be treated quickly. 
Decisions regarding the presence of withdrawal 
are hard to make. A scoring system was 
developed to evaluate signs and symptoms in 
children experiencing withdrawal reaction.lo7 We 
modified it to include other findings we associate 
with withdrawal (Table 1). In a PICU, a score 
higher than 8 is considered to be withdrawal. 
Many scores are available for neonates born to 
addicted mothers; most are useful for older 
infants and children in the ICU when applied 
in  d i v i d u a 11 y. However, c o m p a r a t iv e d a t a 
evaluating their efficacy are lacking, making it 
hard to choose the right one. 
Children who awake from sedation in a strange 
environment may have many disturbed reactions. 
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In addition, although they have been sedated, 
they have not necessarily had sleep, particularly 
rapid eye movement (REM) sleep, and some 
reactions thought to indicate withdrawal are 
characteristic of deprivation of REM sleep. lo8 
Many sedative drugs deplete the brain of central 
neurotransmitters. This imbalance results in 
inability to experience REM sleep and may also 
be responsible for producing some of the 
reactions seen on emergence from sedation. The 
emergence reaction resembles central anti- 
cholinergic syndrome and can be readily treated 
with physostigmine. 
When it is clear that the patient is withdrawing, 
a weaning program should be insti tuted.  
Methadone is a good choice for narcotic 
withdrawal because it has a lower frequency of 
inappropriate opioid binding than morphine, and 
its long duration of action and good 
bioavailability make i t  effective.10g. 110 To 
determine the amount of narcotic needed per day, 
the 24-hour requirement for the intravenous 
opioid currently being given is calculated, and an 
equipotent dose of methadone is given 
intravenously in three to four divided doses. 
Orders should be written for breakthrough doses 
of intravenous methadone 0.05-0.1 mgkg if the 
patient shows sign of withdrawal. After changing 
over to methadone, the patient should be 
stabilized for 24-48 hours with no symptoms of 
withdrawal before beginning to taper the dose. 
The 24-hour dose is then decreased by 10-20% 
every day. The rate of tapering may have to be 
slowed in small infants to dosage reductions of 
10-20% per week. In the event that the child 
does exhibit withdrawal symptoms with a 
tapered dosage, the dosage before the taper 
should be resumed and the drug titrated down 
again at a slower rate. This regimen is used by 
several institutions including our 110 A 
similar regimen may be adopted for orally 
administered opioids. l l 1  
Oral clonidine 3-5 pgkg every 8 hours may 
also minimize withdrawal symptoms and allow 
faster weaning of the narcotic. Hypotension is 
rarely a problem, but bradycardia may occur and 
necessitates decreasing the dosage or  
discontinuing clonidine. If clonidine is given to 
facilitate weaning, it should be tapered over 5-7 
days if the patient has been receiving it for more 
than 6 days.11z-116 
When continuous intravenous infusions of 
sedative are given for more than 48 hours,  
gradual tapering of the agent(s) is recommended. 
This is particularly true for propofol and 
midazolam. Weaning propofol at a rate of 10% 
every 2-3 hours usually keeps the patient from 
with drawing."'^ When midazolam is given for 
prolonged periods, lorazepam is often substituted 
because of its long duration of action and 
availability of an oral formulation. Usually 
lorazepam 0.02-0.05 mg/kg orally or 
intravenously every 8 hours together with 
additional doses of 0.05 m&g every 2 hours as 
necessary for breakthrough withdrawal 
symptoms will keep the child from withdrawing. 
Once stabilized, the dosage is slowly decreased 
by 20 % every 48 hours.”’ 
Summary 
The ideal sedative drug does not exist, and 
tolerance will develop over time with all, the 
drugs discussed. An approach that focuses on 
the patient’s specific needs, balancing sedation, 
analgesia, and amnesia requirements, provides 
the best results. This extensive evaluation of the 
literature suggests that there is no one right way 
of achieving sedation in  children. Many 
roadblocks exist, including lack of validated 
scoring systems that can measure the degree of 
sedation with accuracy and difficulty identifyng 
the presence of withdrawal. A s  long as 
subjectivity is associated with measuring 
sedation, the results of clinical studies will 
remain inconsistent and biased. 
Until good scoring systems are developed, it 
seems wise to become familiar with and follow 
the practice guidelines developed by the Society 
for Critical Care Medicine. Although they were 
developed for adults, extrapolation to children 
using age-appropriate dosing seems reasonable, 
since the recommendations are already applied in 
many pediatric institutions. The guidelines are 
relatively safe, conservative, easy to follow, and, 
to some degree, take cost issues into account. 
It is better for practitioners to administer drugs 
with which they are familiar than to give a 
different drug for each situation. Combining a 
primary technique with knowledge of what 
additions will do can optimize sedation and 
minimize the frequency of side effects. A method 
for evaluating the particular circumstance and 
developing an algorithm to adjust the sedation 
are also vital to effective sedation management. 
Future research should address some of these 
challenges faced by today’s practitioners. 
References 
1. Macnab AJ, Levine M, Glick N, et al. A research tool for 
SEDATION IN CHILDREN Bhatt-Mehta and Rosen 805 
measurement of recovery from sedation: the Vancouver 
sedative recovery scale. J Pediatr Surg 1991;26:1263-7. 
2. Chernik DA, Tucker M, Giglu B, et al. Validity and reliability 
of the neurobehavioral assessment scale. J Clin Pharmacol 
1992;12:43-8. 
3. Veselis RA, Reinsel R, Sommer S ,  et al. Use of neural 
network analysis to classify electroencephalographic patterns 
against depth of midazolam sedation in intensive care unit 
patients. J Clin Monit 1991;7:259-67. 
4. Bullock EA, Shaddy RE. Relaxation and imagery techniques 
without sedation during right ventricular endomyocardial 
biopsy in pediatric heart transplant patients. J Heart Lung 
Transplant 1993-4;12:59-62. 
5. Stevenson JG, French JW, Tenckhoff L, et al. Video viewing 
as an alternative to sedation for young subjects who have 
cardiac ultrasound examinations. J Am SOC Echocardiogr 
1990;3:48&90. 
6. Kaufmann RE, Banner W, Berlin CM, et al. Guidelines for 
monitoring and management of pediatric patients during and 
after sedation for diagnostic and therapeutic procedures. 
Pediatrics 1992;89: 11 10-14. 
7. Holzman RS, Cullen DJ, Eichhorn JH, et al. Guidelines for 
sedation by nonanesthesiologists during diagnostic and 
therapeutic procedures. J Clin Anesth 1994;6:265-76. 
8. Greenberg SB, Faerber EN, Aspinall CL. High dose chloral 
hydrate sedation for children undergoing CT. J Comput Assist 
Tomgr 1991;15:467-9. 
9. Rumm PD, Takao RT, Fox DJ, Atkinson SW. Efficacy of 
sedation of children with chloral hydrate. South Med J 
1990;83:1040-3. 
10. Jaafar MS, Kazi GA. Effect of chloral hydrate sedation on the 
intraocular pressure measurement. J Pediatr Ophthalmol 
Strabismus 1993;30:372-6. 
11. Vade A, Sukhan R, Dolenga M, et  al. Chloral hydrate 
sedation of children undergoing CT and MR imaging: safety as 
judged by American Academy of Pediatrics guidelines. AJR 
12. American Academy of Pediatrics. Use of chloral hydrate for 
sedation in children. Pediatrics 1993;92:471-3. 
13. Wilson S. Chloral hydrate and its effects on multiple 
physiologic parameters in young children: a dose response 
study. Pediatr Dent 1992;14:171-7. 
14. Bennett SN, McNeil MM, Bland LA, et al. Postoperative 
infections traced to contamination of an intravenous 
anesthetic propofol. N Engl J Med 1995;333:147-54. 
15. Zeneca Pharmaceuticals. Diprivan (propofol) package insert. 
Wilmington, DE; 1996. 
16. Oei-Lim LB, Vermeleulen-Cranch DM, Bouvy-Berends EC. 
Conscious sedation with propofol in dentistry. Br Dent J 
199 1 ; 170:34&2. 
17. Stephens AJ, Sapsford DJ, Curzon ME. Intravenous sedation 
for handicapped dental patients: a clinical trial of midazolam 
and propofol. Br DentJ 1993;175:20-5. 
18. Frankville DD, Spear RM, Dyck JB. The dose of propofol 
required to prevent children from moving during magnetic 
resonance imaging. Anesthesiology 1993;79:953-8. 
19. Trotter C, Serpell MG. Neurological sequelae in children 
after prolonged propofol infusion. Anaesthesia 
1992;47:340-2. 
20. Norreslet J, Wahlgreen CW. Propofol infusion for sedation in 
children. Crit Care Med 1990;48:890-2. 
21. Rogers EM. Diprivan intensive care sedation in children. Br J 
Anaesth 1991;67:505. 
22. Reed MD, Yamashita TS, Marx CM, e t  al. The 
pharmacokinetically based propofol dosing strategy for 
sedation of the critically ill, mechanically ventilated patient. 
Crit Care Med 1996;9:1473-81. 
23. Marx SM, Smith PG, Lowrie LH, et al. Optimal sedation of 
mechanically ventilated pediatric critical care patients. Crit 
Care Med 1994;22:163-70. 
24. Hams CE, Grounds RM, Murray AM, et al. Propofol for long 
term sedation in the intensive care unit. Anaesthesia 
1990;45:366-72. 
1995;165:905-9. 
25. Laxenaire MC, Mata-Bermejo E, Moneret-Vautrin DA, et al. 
Life-threatening anaphylactoid reactions to propofol 
(Diprivan). Anesthesiology 1992;77:275-80. 
26. Freysz M, Timour Q, Bertoix 1 ,  et al. Propofol bradycardia. 
Can J Anaesth 1991;38:137-8. 
27. Valente JF, Anderson GL, Branson RD, et al. Disadvantages 
of prolonged propofol sedation in the critical care unit. Crit 
Care Med 1994;22:710-12. 
28. Parke TJ. Stevens JE, Rice ASC, et al. Metabolic acidosis and 
fatal myocardial failure after propofol infusion in children: 
five case reports. Br Med J 1992;305:613-16. 
29. Endresen BE, Bruk AV. Propofol (Diprivan) ti1 barn. Tidsskr 
Nor Laegeforen 1992;112:1636-7. 
30. FDA’s Anesthetic and Life Support  Drug Advisory 
Committee. Health News Daily. September 2, 1992. 
31. Chan L, Tan CL. Use of intravenous midazolam for sedation 
in children undergoing ward procedures. J Singapore Paediatr 
SOC 1992;34:30-3. 
32. Payne KA, Coetzee AR, Mattheyse FJ, et al. Oral midazolam 
in pediatric premedication. S Afr Med J 1991;79:372-5. 
33. Bhatt-Mehta V, Johnson CE, Kostoff L, et al. Stability of 
midazolam hydrochloride in extemporaneously prepared 
flavored gelatin. Am J Hosp Pharm 1993;50:472-5. 
34. Alderson PJ, Lerman J.  Oral premedication for pediatric 
ambulatory anaesthesia: a comparison of midazolam and 
ketamine. Can J Anaesth 1994;41:221-6. 
35. Levine MF, Spahr-Schopfer IA, Hartley E, e t  al. Oral 
midazolam premedication in children: the minimum time 
interval for separation from parents. Can J Anaesth 
1993;40726-9. 
36. Wilton NCT, Leigh J,  Rosen DR, et al. Preanesthetic sedation 
of preschool children using intranasal midazolam. 
Anesthesiology 1988;69:972-5. 
37. Saint-Maurice C, Meistelman C, Rey E, e t  al. The 
pharmacokinetics of rectal midazolam for premedication in 
children. Anesthesiology 1986;65:536-8. 
38. van der Bijl P, Roelofse JA, Stander 1A. Rectal ketamine and 
midazolam for premedication in pediatric dentistry. J Oral 
Maxillofac Surg 1991;49:10504. 
39. Silvasi DL, Rosen DA, Rosen KR. Continuous intravenous 
midazolam infusion for sedation in the pediatric intensive care 
unit. Anesth Analg 1988;67:266-8. 
40. Rosen DA, Rosen KR. Midazolam for sedation in the 
paediatric intensive care unit. Intensive Care Med 
41. Hartwig S, Roth B, Theisohn M. Clinical experience with 
continuous intravenous sedation using midazolam and 
fentanyl in the pediatric intensive care unit. Eur J Pediatr 
1991;150:784-8. 
42. Yaster M, Nichols DG, Deshpande JK, et  al. Midazolam- 
fentanyl intravenous sedation in children: case report of 
respiratory arrest. Pediatrics 1990;86:463-7. 
43. Doyle WL. Emergence delirium in a child given oral 
midazolam for conscious sedation. Ann Emerg Med 
1994;24:1173-5. 
44. Relling MV, Mulhern RK, Dodge RK, e t  al. Lorazepam 
pharmacodynamics and pharmacokinetics in children. J 
Pediatr 1989;114:641-6. 
45. Shapiro BA, Warren J ,  Ego1 AB, et al. Practice parameters for 
intravenous analgesia and sedation for adult patients in the 
intensive care unit: an executive summary. Crit Care Med 
1995;23:1596-1600. 
46. Pohlman AS, Simpson KR, Hall JB. Continuous intravenous 
infusion of lorazepam versus midazolam for sedation during 
mechanical ventilatory support. A prospective, randomized 
study. Crit Care Med 1994;22:1241-7. 
47. Tobias JD. Lorazepam vs midazolam for sedation [letter]. Crit 
Care Med 1995;23:1151-2. 
48. Hoey LL, Vance-Bryan K, Clarens DM, et al. Lorazepam 
stability in parenteral solution for continuous intravenous 
administration. Ann Pharmacother 1996;30:343-6. 
49. Trissel LA, Pearson SD. Storage of lorazepam in three 
injectable solutions in polyvinyl chloride and polyolefin bags. 
199 1 ; 17(suppl):S 15-19. 
806 PHARMACOTHERAPY Volume 18, Number 4, 1998 
Am J Hosp Pharm 1993;51:368-72. 
50. Cronin CMG. Neurotoxicity of lorazepam in a premature 
infant. Pediatrics 1992;89:1129-30. 
51. Marshall JD, Farrar HC, Kearns GL. Diarrhea associated with 
enteral benzodiazepine solutions. J Pediatr 1994;126:657-9. 
52. Grillo HC, Matheson DJ. Surgical management of tracheal 
strictures. Surg Clin North Am 1988;68:511-24. 
53. Harrison MR, Heldt GP, Brasch RC, et al. Resection of distal 
tracheal stenosis in a baby with agenesis of the lung. Pediatr 
Surg 1980;15:938-43. 
54. Tobias  JD.  Phipps  S,  Smi th  B, et  a l .  Oral ketamine 
premedication to alleviate the distress of invasive procedures 
in pediatric oncology patients. Pediatrics 1992;90:537-41. 
55. Rosen DA, Rosen KR, Elkins TE. Ketamine clinic: a model 
clinic for sedation of mentally handicapped patients 
undergoing routine gynecological examinations. In: Domino 
EF, ed. Status of ketamine in anesthesiology. Ann Arbor, MI: 
Npp Books, 1990:337-42. 
56. Rosenberg M. Oral ketamine for deep sedation of difficult to 
manage children who are mentally handicapped: case report. 
Pediatr Dent 1991;13:221-3. 
57. Rosen DA, Rosen KR, Elkins TE, et al. Outpatient sedation: 
an essential addition to gynecologic care for persons with 
mental retardation. Am J Obstet Gynecol 1991;164:825-8. 
58. Weksler N, Ovadia L, Muati G, et al. Nasal ketamine for 
pediatric premedication. Can J Anaesth 1993;40:119-21. 
59. Green SM. Ketamine sedation for pediatric procedures. 1. 
Prospective series. Ann Emerg Med 1990;19:1024-32. 
60. Greene CA, Gillette PC, Fyfe DA. Frequency of respiratory 
compromise after ketamine sedation for cardiac 
catheterization in patients < 21 years of age. Am J Cardiol 
1991;68:1116-17. 
61. Morray JP, Lynn AM, Stamm SJ, et al. Hemodynamic effects 
of ketamine in children with congenital heart disease. Anesth 
Analg 1984;63:895-9. 
62. Berman W, Fripp RR, Rubler M, et al. Hemodynamic effects 
of ketamine in children undergoing cardiac Catheterization. 
Pediatr Cardiol 1990;18:19-21. 
63. Tobias JD, Mortin LD, Wetzel RC. Ketamine by continuous 
infusion for sedation in the pediatric intensive care unit. Crit 
Care Med 1990;18:819-21. 
64. Hartvig P, Larsson E, Joachimsson P. Postoperative analgesia 
and sedation after pediatric cardiac surgery using a constant 
infusion of ketamine. J Cardiothorac Vasc Anesth 
1993;7:148-53. 
65. Bucholtz JD. Issues concerning the sedation of children for 
radiation therapy. Oncol Nurs Forum 1992;19:649-55. 
66. Bloomfield EL, Masaryk TJ, Caplin A, et al. Intravenous 
sedation for MR imaging of the brain and spine in children: 
pentobarbital versus propofol. Radiology 1993; 186:93-7. 
67. Nahata MC, Starling S, Edwards RC. Prolonged sedation 
associated with secobarbital in newborn infants receiving 
ventilatory support. Am J Perinatol 1991;8:35-6. 
68. Schoch JP, Robert R, Ramboatiana R, et  al. Methohexital 
intramusculaire. Un protocole danesthesie simple et fiable 
pour  scannner  cerebral  chez I’enfant. Agressologie 
1990;31:45-8. 
69. Manuli MA, Davies L. Rectal methohexital for sedation of 
children during imaging procedures. AJR 1993;160:577-80. 
70. Schwanda AE, Freyer DR, Sanfil ippo DJ, e t  a l .  Brief 
unconscious sedation for painful pediatric oncology 
procedures. Intravenous methohexital with appropriate 
monitoring is safe and effective. Am J Pediatr Hematol Oncol 
1993; 15:370-6. 
71. Rautiainen P. Alfentanil for sedation in infants and children 
during cardiac catheterization. Can J Anaesth 1991;38:980-4. 
72. Meretoja OA, Rautiainen P. Alfentanil and fentanil sedation 
in infants and small children during cardiac catheterization. 
Can J Anaesth 1990;37:624-8. 
73. Rautiainen P. Alfentanil sedation for cardiac catheterization of 
children with fontan shunts. Can J Anaesth 1992;39:944-8. 
74. Roth B, Schlunder C, Houben F, et al. Analgesia and sedation 
in neonatal intensive care using fentanil by continuous 
infusion. Dev Pharamacol Ther 1991;17:121-7. 
75. Lind GH, Marcus MA, Mears SL, et al. Oral transmucosal 
fentanyl citrate for analgesia and sedation in the emergency 
department. Ann Emerg Med 1991;20:1117-20. 
76. Streisand JB, Ashburn M, LeMarie L, et al. Bioavailability and 
absorption of oral transmucosal fentanyl citrate [abstr]. 
Anesthesiology 1990;73:A369. 
77. Kroll W ,  List WF.  Eignet sich sufentanil  fur die 
langzeitsedierung krit ish kranker?  Anaesthetist 
1992;41:271-5. 
78. Hughes J .  Leach HJ, Choonara  I .  Hallucinations on 
withdrawal of isoflurane used, as sedation. Acta Pediatr 
79. Spencer EM, Willatts SM. lsoflurane for prolonged sedation 
in the intensive care uni t .  Intensive Care Med 
1992;18:$15-21. 
80. Millane TA, Bennett ED, Grounds RM. lsoflurane and 
propofol for long term sedation in the intensive care unit. 
Anaesthesia 1992;47:768-74. 
81. Shapira J ,  Holan G, Guelmann M, et al. Evaluation of the 
effect of nitrous oxide and hydroxyzine in controlling the 
behavior of the pediatric dental  patient.  Pediatr Dent 
82. Garcia-Guiral  M, Carrera  A, Lora-Tamayo J,,et, al. 
Prernedication with clonidine in the neurosurgical patient: 
sedation, anesthetic requirements and  hemodynamic 
perfusion. Rev EBp Anestesiol 1994;41:77-81. 
83. Buhrer M, Mappes A, Lauber R, e t  al. Dexmetomidine 
decreases thiopentone dose requirement and alters dis- 
tribution pharmacokinetics. Aneithesiology 1994;80:1216-27. 
84. Keeter S, Benator RM, Weinberg SM, et  al. Sedation in 
pediatric CT: national survey of current practice. Radiology 
1990;175:745-52. 
85. Hubbard AM, Markowitz R1, Kimmel B, et al. Sedation for 
pediatric patients undergoing CT and MRI. J Comput Assist 
Tomogr 1992;16:3-6. 
86. Coventry DM, Martin CS, Burke AM. Sedation in paediatric 
computerized tomography-a double blind assessment of 
rectal midazolam. Eur J Anaesthesiol 1991;829-32. 
87. Stevenson JG, Kawabori 1, French JW. Doppler pressure 
gradient estimation in children: accuracy, effect of activity and 
exercise, and the need for sedation during examination. Acta 
Paediatr Scand 1986;5329:78-86. 
88. Latson LA, Cheatham JP, Gumbiner CA. Midazolam nose 
drops for outpatient echocardiography sedation in infants. Am 
Heart J 1991;121:209-10. 
89. Krafft TC, Kramer N, Kunzelmann KH, et al. Experience 
with midazolam as sedative in the dental treatment of 
uncooperative children. ASDC J Dent Child 1993;60:295-9. 
90. Kramer N ,  Krafft T, Kunzelmann KH, e t  al. 
Milchzahnbehandlung unter Sedierung mit rektal appliziertem 
midazolam. Dtsch Zahnarztl Z 1991;46:609-11. 
91. Sams DR, Thornton JB, Wright JT. The assessment of two 
oral sedation drug regimens in pediatric dental patients. ASDC 
J Dent Child. 1992;59:306-12. 
92. Sams DR, Cook EW, Jackson  J G ,  e t  al .  Behavioral 
assessments of two drug combinations for oral sedation. 
Pediatr Dent 1993;15:186-90. 
93. Tsinidou KG, Curzon ME, Sapsford DJ. A study to compare 
the effectiveness of temazepam and a chloral hydrate/ 
hydroxyzine combination in sedating paediatric dental 
patients. Int J Paediatr Dent 1992;2:163-9. 
94. Songvasin C, Pasavorakul A. A comparison of the child’s 
behavior between two groups of oral sedative drugs. J Dent 
Assoc Thai 1990;40:23745. 
95. Meyer ML, Mourino AP, Farrington FH. Comparison of 
triazolam to chloral hydrate/hydroxyzine combination in 
sedation of pediatric dental  patients.  Pediatr Dent 
1990; 12:283-7. 
96. Hasty MF, Vann WF Jr, Dilley DC, et al. Conscious sedation 
of pediatric dental patients: an investigation of chloral 
hydrate, hydroxyzine pamoate, and meperidine vs chloral 
hydrate and hydroxyzine pamoate. Pediatr Dent 1991;13: 
1993;82:885-6. 
1992;14:167-70. 
SEDATION IN CHILDREN Bhatt-Mehta and Rosen 807 
10-19. 
97. Poorman TL, Farrington FH, Mourino AP. Comparison of a 
chloral hydrate hydroxyzine combination with and without 
meperidine in the sedation of pediatric dental patients. Pediatr 
Dent 1990; 12:288-91. 
98. Alfonzo-Echeverri EC, Berg JH, Wild TW, e t  al .  Oral 
ketamine for pediatric outpatient dental surgery. Pediatr Dent 
1993; 15: 182-5. 
99. Roberts SM, Wilson CF, Seale NS, e t  al. Evaluation of 
morphine as compared to meperidine when administered to 
the moderately anxious pediatric dental patient. Pediatr Dent 
1992; 14:306-13. 
100. Sandler ES, Weyman C, Connor C, et al. Midazolam versus 
fentanyl as premedication for painful procedures in children 
with cancer. Pediatrics 1992;89:631-4. 
101. Pratila MG, Fischer ME, Alagesan R, et al. Propofol versus 
midazolam for monitored sedation: a comparison of 
intraoperative and  recovery parameters. J Clin Anesth 
1993;5:268-74. 
102. Hoffman P, Schockenhoff B, Lierz P. Analgosedierung des 
beatmeten intensivpatienten. Klin Wochenschr 1991;69:72-9. 
103. Weyland W, Brauer A, Weyland A, et al. U Der Einfluss von 
Sedierung auf die Sauerstoffaufnahme unter spontanatmung. 
Anaesthetist 1993;42:391-5. 
104. Bahal-OMara N, Nahata MC, Murray RD, et al. Efficacy of 
diazepam and meperidine in ambulatory pediatric patients 
undergoing endoscopy: a randomized, double-blind trial. J 
Pediatr Gastroenterol Nutr 1993;16:387-92. 
105. Katz R, Kelly HW. Prospective study on the occurrence of 
withdrawal in critically ill children who received fentanyl by 
continuous infusion. Crit Care Med 1994;22:763-7. 
106. van Engelen BG, Gimbrere JS, Booy LH. Benzodiazepine 
withdrawal reaction in two children after discontinuation of 
sedation with midazolam. Ann Phannacother 1993;27:579-81. 
107. Finnegan LP, Kron RE, Connaughton JF Jr, et al. Neonatal 
abstinence syndrome: assessment and management. Int J 
Addict Dise 1975;2:141-58. 
108. Dinges DF, Davis MM, Glass P, et al. Fetal exposure to 
narcotics. Neonatal sleep as a measure of nervous system 
disturbance. Science 1980;209:619-21. 
109. Tobias JD, Schleien CL, Haun SE. Methadone treatment for 
iatrogenic narcotic dependency in pediatric intensive care unit 
patients. Crit Care Med 1990;18:1292-3. 
110. Anand KJS, Arnold JH. Opioid tolerance and dependence in 
infants and children. Crit Care Med 1994;22:33442. 
11 1. Schilling CG, Seay RS, Sommers NL, et al. Development of a 
narcotic wean service in a pediatric tertiary care setting 
[abstr]. Pharmacotherapy 1995;15: 121. 
112. Agren H. Clonidine treatment of the opiate withdrawal 
syndrome. A review of clinical trials of a theory. Acta 
Psychiatr Scand Suppl 1986;327:91-113. 
113. Boyd EM. Clonidine for opiate withdrawal [letter]. Am Fam 
Physician 1986;33:42. 
114. Kleber HD, Gold MS, Riordan CE. The use of clonidine in 
detoxification from opiates. Bull Narc 1980;32:1-10. 
115. Deveyani P, Mitwalli A, Graham W. Clonidine therapy for 
narcotic withdrawal. Can Med Assoc J 1982;127:1009-11. 
116. Holman PW. Clonidine and naloxone in ultrashort opiate 
detoxification. Clin Pharm 1985;4: 100-2. 
117. Beller JP, Pottecher T, Lugnier A, et al. Prolonged sedation 
with propofol in ICU patients:  recovery and  blood 
concentration changes during periodic interruptions in 
infusion. Br J Anaesth 1988;61:583-8. 
118. Grant 1, Worsley M. Withdrawal syndrome after propofol. 
Anaesthesia 199 1 ;46: 238. 
119. Yaster M, Berde C, Billet C. The management of opioid and 
benzodiazepine dependence in infants,  children and  
adolescents. Pediatrics 1996;98: 135-9. 
